AstraZeneca says detained China head has lawyer

AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesday.
AstraZeneca says China has detained a senior executive
The company believes Chinese authorities are probing allegations that two current and two former employees had illegally imported cancer drugs.
AstraZeneca’s China Head Taken Into Custody by Chinese Authorities: Reports
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days after it was reported that he was under investigation for alleged medical insurance fraud in the country.
AstraZeneca Says Current, Former Executives Involved in China Probe
Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe into alleged breaches of laws around drug importation and data privacy, the company said.
AstraZeneca CEO says detained China chief has a lawyer but 'we have no information'
AstraZeneca's CEO said on Tuesday that the company's China president Leon Wang, who last month was detained by Chinese authorities, has a lawyer he is in touch with, but "we have no information as a company".
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
AstraZeneca chief taking arrest of Chinese executive ‘very seriously’
AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very seriously”. Mr Soriot pledged on Tuesday to “fully cooperate with the authorities” in the country after the arrest of its China president,

AstraZeneca Raises Outlook on Earnings

AstraZeneca Talks Up US Growth as China Problems Worsen
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca Plc (NASDAQ:AZN) reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency ...
Pharma Giant AstraZeneca Takes China Probes 'Very Seriously'
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention ...
FiercePharma10h
AstraZeneca CEO defends corporate oversight, $80B revenue target amid China probes
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
AstraZeneca's China chief in custody, believes unrelated to insurance probe
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...
Investopedia on MSN6d
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an ...
AstraZeneca Expands U.S. Investment Plan -- 3rd Update
The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...